CTOs on the Move

Mosaic Biosciences

www.mosaicbio.com

 
Mosaic`s biopharmaceutical teams turn ideas into reality. We provide experienced biopharma leadership and cross-functional teams to accelerate your protein therapeutic research and development program
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Mosaic Biosciences raised $11.4M on 06/14/2022

Similar Companies

HomeDNA

HomeDNA, Inc. is a Keller, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcadia Biosciences

Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia`s GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company`s portfolio of agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment.

Keros Therapeutics

Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases

Elevai Labs

ELEVAI LABS, INC. is a biotechnology company developing cutting-edge regenerative skincare applications. The company solves the unmet needs in the regenerative aesthetics space through a combination of cutting-edge science and next-generation consumer applications. Elevai Labs develops state-of-the-art topic anesthetic and pharmaceutical-grade skin care for the physician-dispensed market, with a focus on leveraging stem cell exosome technology.

T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.